ATE530645T1 - Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine - Google Patents

Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine

Info

Publication number
ATE530645T1
ATE530645T1 AT09150098T AT09150098T ATE530645T1 AT E530645 T1 ATE530645 T1 AT E530645T1 AT 09150098 T AT09150098 T AT 09150098T AT 09150098 T AT09150098 T AT 09150098T AT E530645 T1 ATE530645 T1 AT E530645T1
Authority
AT
Austria
Prior art keywords
avermectine
ratio
streptomyces avermitilis
gene regulating
avermitilis gene
Prior art date
Application number
AT09150098T
Other languages
English (en)
Inventor
Kim Stutzman-Engwall
Claes Gustafsson
Anke Krebber
Sun RAILLARD
Jeremy Minshull
Seran Kim
Yan Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE530645T1 publication Critical patent/ATE530645T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C12P19/623—Avermectin; Milbemycin; Ivermectin; C-076

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT09150098T 2002-02-12 2003-01-31 Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine ATE530645T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35622202P 2002-02-12 2002-02-12

Publications (1)

Publication Number Publication Date
ATE530645T1 true ATE530645T1 (de) 2011-11-15

Family

ID=27734621

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03739390T ATE426659T1 (de) 2002-02-12 2003-01-31 Streptomyces avermitilis gen zur regulierung des verhaltnisses der b2:b1 avermectine
AT09150098T ATE530645T1 (de) 2002-02-12 2003-01-31 Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03739390T ATE426659T1 (de) 2002-02-12 2003-01-31 Streptomyces avermitilis gen zur regulierung des verhaltnisses der b2:b1 avermectine

Country Status (25)

Country Link
US (2) US7388085B2 (de)
EP (2) EP2050815B1 (de)
JP (1) JP2005517406A (de)
KR (1) KR100718378B1 (de)
CN (2) CN102392028B (de)
AR (1) AR038405A1 (de)
AT (2) ATE426659T1 (de)
AU (1) AU2003245052B2 (de)
BR (1) BRPI0307620B8 (de)
CA (1) CA2475214C (de)
CY (2) CY1110454T1 (de)
DE (1) DE60326824D1 (de)
DK (2) DK2050815T3 (de)
ES (2) ES2373629T3 (de)
IL (3) IL162866A0 (de)
ME (1) ME00472B (de)
MX (1) MXPA04007777A (de)
PL (1) PL211693B1 (de)
PT (2) PT2050815E (de)
RS (1) RS50813B (de)
RU (1) RU2293117C2 (de)
SI (2) SI1476539T1 (de)
TW (1) TWI341330B (de)
WO (1) WO2003068955A2 (de)
ZA (1) ZA200405345B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50813B (sr) 2002-02-12 2010-08-31 Pfizer Products Inc. Streptomyces avermitilis gen koji određuje odnos b2:b1 avermektina
CN102241750B (zh) * 2010-05-14 2014-05-28 中国科学院微生物研究所 一种生产阿维菌素的基因工程方法及其专用菌株
CN102093997B (zh) * 2010-12-01 2013-03-13 中国科学院上海有机化学研究所 一种改造除虫链霉菌产生多拉菌素的方法
CN109576196B (zh) * 2019-01-25 2022-01-04 北大方正集团有限公司 一种生产多拉菌素的发酵培养基及多拉菌素的生产方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4429042A (en) 1978-09-08 1984-01-31 Merck & Co., Inc. Strain of Streptomyces for producing antiparasitic compounds
IN167980B (de) 1987-01-23 1991-01-19 Pfizer
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
CZ287404B6 (en) * 1993-10-05 2000-11-15 Pfizer Process for preparing doramectin
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
PL194270B1 (pl) 1998-02-13 2007-05-31 Pfizer Prod Inc Wyizolowana cząsteczka polinukleotydowa, cząsteczka oligonukleotydowa, zrekombinowany wektor, komórka gospodarza, wyizolowany produkt genu AveC S. avermitilis, wyizolowany produkt homologu genu AveC S. hygroscopicus, sposób wytwarzania zrekombinowanego produktu genu AveC, sposób wytwarzania zrekombinowanego produktu homologu genu AveC, cząsteczka polinukleotydowa, wektor do zastępowania genu, sposób identyfikowania mutacji otwartej ramki odczytuAveC, sposób wytwarzania nowych szczepów S. avermitilis, szczep S. avermitilis i sposób wytwarzaniaawermektyn
US6248579B1 (en) * 1998-02-13 2001-06-19 Pfizer Inc Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
RU2156301C2 (ru) * 1998-06-09 2000-09-20 Мосин Владимир Александрович Штамм актиномицета streptomyces avermitilis ссм 4697 - продуцент авермектинов
US6197591B1 (en) 1998-09-14 2001-03-06 Pfizer Inc. Streptomyces avermitilis regulatory genes for increased avermectin production
WO2001012821A1 (en) * 1999-08-12 2001-02-22 Pfizer Products Inc. Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
DE60039616D1 (de) 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
RS50813B (sr) * 2002-02-12 2010-08-31 Pfizer Products Inc. Streptomyces avermitilis gen koji određuje odnos b2:b1 avermektina

Also Published As

Publication number Publication date
DK2050815T3 (da) 2011-12-12
HK1168383A1 (en) 2012-12-28
RU2004124521A (ru) 2005-04-10
CY1112491T1 (el) 2015-12-09
CY1110454T1 (el) 2015-04-29
IL192371A (en) 2010-11-30
KR100718378B1 (ko) 2007-05-14
IL192371A0 (en) 2008-12-29
CN1630712B (zh) 2011-09-28
BRPI0307620B1 (pt) 2015-08-11
IL162866A0 (en) 2005-11-20
PT1476539E (pt) 2009-04-09
AU2003245052B2 (en) 2008-07-31
TWI341330B (en) 2011-05-01
EP2050815A1 (de) 2009-04-22
KR20040081199A (ko) 2004-09-20
SI2050815T1 (sl) 2012-01-31
EP1476539A2 (de) 2004-11-17
US7388085B2 (en) 2008-06-17
AR038405A1 (es) 2005-01-12
CN102392028B (zh) 2013-08-14
ZA200405345B (en) 2005-06-14
CA2475214C (en) 2012-07-31
PL371320A1 (en) 2005-06-13
EP2050815B1 (de) 2011-10-26
SI1476539T1 (sl) 2009-06-30
TW200303918A (en) 2003-09-16
RS70004A (sr) 2006-10-27
US20090017508A1 (en) 2009-01-15
ES2373629T3 (es) 2012-02-07
RU2293117C2 (ru) 2007-02-10
DK1476539T3 (da) 2009-05-11
ATE426659T1 (de) 2009-04-15
US8008078B2 (en) 2011-08-30
RS50813B (sr) 2010-08-31
US20030166165A1 (en) 2003-09-04
IL162866A (en) 2009-11-18
PL211693B1 (pl) 2012-06-29
JP2005517406A (ja) 2005-06-16
MXPA04007777A (es) 2004-10-15
WO2003068955A3 (en) 2003-11-13
EP1476539B1 (de) 2009-03-25
AU2003245052A1 (en) 2003-09-04
HK1074644A1 (en) 2005-11-18
BRPI0307620B8 (pt) 2016-09-13
CN1630712A (zh) 2005-06-22
WO2003068955A2 (en) 2003-08-21
CA2475214A1 (en) 2003-08-21
PT2050815E (pt) 2012-01-02
CN102392028A (zh) 2012-03-28
ES2321827T3 (es) 2009-06-12
BR0307620A (pt) 2004-12-07
DE60326824D1 (de) 2009-05-07
ME00472B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
AU2003901956A0 (en) Game
EP1680409A4 (de) Ph-wert-empfindliche prodrugs von 2,6-diisopropylphenol
AU2003238324A1 (en) Multiple game block assembly
ATE426659T1 (de) Streptomyces avermitilis gen zur regulierung des verhaltnisses der b2:b1 avermectine
ATE283363T1 (de) Streptomyces avermitilis gen zum regulieren des verhältnisses der b2:b1 avermectinen
ATE341632T1 (de) Streptomyces avermitilis gen zum regulieren des verhältnisses der b2:b1 avermectinen
GB2399268B (en) Throttle
GB0311809D0 (en) Humidifier
AU2003100225A4 (en) Game
AU2002100735A4 (en) Brick motar-gap clip
WO2006010077A3 (en) Prodrugs of lonidamine and lonidamine analogs
GB2400625B (en) Arches
GB2403231B (en) Self spacing brick
ES1051546Y (es) Expositor-contenedor de estuches con juegos o grupos de destornilladores.
GB0310457D0 (en) Enzyme
AU2003261669A1 (en) Partially narrowed brick
GB0327838D0 (en) Foresight
AU2003904038A0 (en) The footy (sports) brick
GB0328461D0 (en) Scatter rocket
AU2003906259A0 (en) Lottery
AU2003900803A0 (en) Winners-m lottery
GB0300435D0 (en) The game of muddles
PL364058A1 (en) Furnace for the bio-fireplace
GB0320279D0 (en) Furnace
GB0319579D0 (en) Enzyme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2050815

Country of ref document: EP